A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ

Berberine (BBR) exerts specific therapeutic effects on various diseases such as diabetes, obesity, and other inflammation-associated diseases. However, the low oral bioavailability (below 1%) of berberine due to its poor solubility and membrane permeability limits its clinical use. In this paper, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Man, Xu, Rong, Liu, Xiaoli, Zhang, Ling, Qiu, Siyan, Lu, Yuting, Zhang, Peng, Yan, Ming, Zhu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374667/
https://www.ncbi.nlm.nih.gov/pubmed/35962183
http://dx.doi.org/10.1038/s42003-022-03776-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374667/
https://www.ncbi.nlm.nih.gov/pubmed/35962183
http://dx.doi.org/10.1038/s42003-022-03776-0

Ejemplares similares